MDA-MB-134-VIHomo sapiens (Human)Cancer cell line
Also known as: MDA-MB-134 VI, MDA MB 134VI, MDA-MB-134VI, MDAMB134VI, MDA-MB-134, MDAMB134, MDA-134, MDA134, MM134, MD Anderson-Metastatic Breast-134-VI, MDA-MD-134VI, MDA-MB-134-IV, MDA-MB-134IV
MDA-MB-134
Quick Overview
Human breast cancer cell line with invasive lobular characteristics and E-cadherin loss.
Detailed Summary
Research Applications
Key Characteristics
Basic Information
| Database ID | CVCL_0617 |
|---|---|
| Species | Homo sapiens (Human) |
| Tissue Source | Pleural effusion[UBERON:UBERON_0000175] |
Donor Information
| Age | 47 |
|---|---|
| Age Category | Adult |
| Sex | Female |
| Race | caucasian |
| Subtype Features | luminal ER+ |
Disease Information
| Disease | Invasive breast lobular carcinoma |
|---|---|
| Lineage | Breast |
| Subtype | Breast Invasive Lobular Carcinoma |
| OncoTree Code | ILC |
DepMap Information
| Source Type | ATCC |
|---|---|
| Source ID | ACH-000044_source |
Known Sequence Variations
| Type | Gene/Protein | Description | Zygosity | Note | Source |
|---|---|---|---|---|---|
| MutationSimple | CDH1 | p.Leu230fs*4 (c.688_832del145) | Homozygous | - | PubMed=19593635 |
| MutationSimple | KRAS | p.Gly12Arg (c.34G>C) | Unspecified | - | PubMed=26124327 |
| MutationSimple | MAP2K4 | p.Ser184Leu (c.551C>T) | Homozygous | - | Unknown, PubMed=19593635, PubMed=9331070 |
| MutationSimple | TP53 | p.Glu285Lys (c.853G>A) | Unspecified | Temperature-sensitive | PubMed=23851445, PubMed=17260012 |
Haplotype Information (STR Profile)
Short Tandem Repeat (STR) profile for cell line authentication.
Loading gene expression data...
Publications
Lobular breast cancer: molecular basis, mouse and cellular models.";
Christgen M., Derksen P.W.B.
Breast Cancer Res. 17:16.1-16.9(2015).
Next-generation characterization of the Cancer Cell Line Encyclopedia.
Sellers W.R.
Nature 569:503-508(2019).
An interactive resource to probe genetic diversity and estimated ancestry in cancer cell lines.
Dutil J., Chen Z.-H., Monteiro A.N.A., Teer J.K., Eschrich S.A.
Cancer Res. 79:1263-1273(2019).
Comprehensive phenotypic characterization of human invasive lobular carcinoma cell lines in 2D and 3D cultures.
Jacobsen B.M., Tseng G.C.-C., Davidson N.E., Oesterreich S.
Cancer Res. 78:6209-6222(2018).
Multidimensional phenotyping of breast cancer cell lines to guide preclinical research.
Lakhani S.R.
Breast Cancer Res. Treat. 167:289-301(2018).
Characterization of human cancer cell lines by reverse-phase protein arrays.
Liang H.
Cancer Cell 31:225-239(2017).
TCLP: an online cancer cell line catalogue integrating HLA type, predicted neo-epitopes, virus and gene expression.
Loewer M., Sahin U., Castle J.C.
Genome Med. 7:118.1-118.7(2015).
A catalog of HLA type, HLA expression, and neo-epitope candidates in human cancer cell lines.
Boegel S., Lower M., Bukur T., Sahin U., Castle J.C.
OncoImmunology 3:e954893.1-e954893.12(2014).
A resource for cell line authentication, annotation and quality control.
Neve R.M.
Nature 520:307-311(2015).
Cell lines from human breast.";
Leibovitz A.
(In book chapter) Atlas of human tumor cell lines; Hay R.J., Park J.-G., Gazdar A.F. (eds.); pp.161-184; Academic Press; New York; USA (1994).
Breast cancer stem cells: tumourspheres and implications for therapy.";
Morrison B.J.
Thesis PhD (2010); Griffith University; Brisbane; Australia.
Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization.
Cailleau R.M., Olive M., Cruciger Q.V.J.
In Vitro 14:911-915(1978).
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
Fogh J., Wright W.C., Loveless J.D.
J. Natl. Cancer Inst. 58:209-214(1977).
Breast tumor cell lines from pleural effusions.";
Cailleau R.M., Young R., Olive M., Reeves W.J. Jr.
J. Natl. Cancer Inst. 53:661-674(1974).
Polymorphic enzyme analysis of cultured human tumor cell lines.";
Dracopoli N.C., Fogh J.
J. Natl. Cancer Inst. 70:469-476(1983).
Identification of cryptic sites of DNA sequence amplification in human breast cancer by chromosome microdissection.
Guan X.-Y., Meltzer P.S., Dalton W.S., Trent J.M.
Nat. Genet. 8:155-161(1994).
Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor.
Skolnick M.H., Tavtigian S.V.
Cancer Res. 57:4177-4182(1997).
Lack of relationship between CDK activity and G1 cyclin expression in breast cancer cells.
Sweeney K.J., Swarbrick A., Sutherland R.L., Musgrove E.A.
Oncogene 16:2865-2878(1998).
Chromosomal alterations in 15 breast cancer cell lines by comparative genomic hybridization and spectral karyotyping.
Isola J.J., Larsson C.
Genes Chromosomes Cancer 28:308-317(2000).
Comparative genomic hybridization analysis of 38 breast cancer cell lines: a basis for interpreting complementary DNA microarray data.
Gooden G.C., Ethier S.P., Kallioniemi A.H., Kallioniemi O.-P.
Cancer Res. 60:4519-4525(2000).
Molecular cytogenetic analysis of breast cancer cell lines.";
Courtay-Cahen C., Roberts I., Theillet C., Caldas C., Edwards P.A.W.
Br. J. Cancer 83:1309-1317(2000).
Aberrations of chromosome 8 in 16 breast cancer cell lines by comparative genomic hybridization, fluorescence in situ hybridization, and spectral karyotyping.
Isola J.J.
Cancer Genet. Cytogenet. 126:1-7(2001).
Reciprocal translocations in breast tumor cell lines: cloning of a t(3;20) that targets the FHIT gene.
Birnbaum D., Chaffanet M.
Genes Chromosomes Cancer 35:204-218(2002).
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Edwards P.A.W., Chaffanet M.
Genes Chromosomes Cancer 37:333-345(2003).
Evidence that both genetic instability and selection contribute to the accumulation of chromosome alterations in cancer.
Edwards P.A.W., Caldas C.
Carcinogenesis 26:923-930(2005).
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
van den Ouweland A.M.W., Merajver S.D., Ethier S.P., Schutte M.
Cancer Res. 66:41-45(2006).
Thirteen new p53 gene mutants identified among 41 human breast cancer cell lines.
Wasielewski M., Elstrodt F., Klijn J.G.M., Berns E.M.J.J., Schutte M.
Breast Cancer Res. Treat. 99:97-101(2006).
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Johnson M.D., Lippman M.E., Ethier S.P., Gazdar A.F., Gray J.W.
Cancer Cell 10:515-527(2006).
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
Pollack J.R.
PLoS ONE 4:E6146-E6146(2009).
Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines.
den Bakker M.A., Foekens J.A., Martens J.W.M., Schutte M.
Breast Cancer Res. Treat. 121:53-64(2010).
Signatures of mutation and selection in the cancer genome.";
Deloukas P., Yang F.-T., Campbell P.J., Futreal P.A., Stratton M.R.
Nature 463:893-898(2010).
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
Nature 483:603-607(2012).
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Martens J.W.M.
Breast Cancer Res. 15:R33.1-R33.17(2013).
Glutamine sensitivity analysis identifies the xCT antiporter as a common triple-negative breast tumor therapeutic target.
McCormick F., Gray J.W.
Cancer Cell 24:450-465(2013).
Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypes.
Harrell J.C., Roman E., Adamo B., Troester M.A., Perou C.M.
Breast Cancer Res. Treat. 142:237-255(2013).
Modeling precision treatment of breast cancer.";
Collisson E.A., van 't Veer L.J., Spellman P.T., Gray J.W.
Genome Biol. 14:R110.1-R110.14(2013).
Invasive lobular carcinoma cell lines are characterized by unique estrogen-mediated gene expression patterns and altered tamoxifen response.
Chandran U.R., Davidson N.E., Dabbs D.J., Welm A.L., Oesterreich S.
Cancer Res. 74:1463-1474(2014).